Figure 4. Pharmacological inhibition of TGF-β signaling ameliorates EAE.

GFAP-luc mice (A–C, n = 4–7 per group) or SBE-luc mice (D, n = 10–12 per group) were immunized with MOG_35–55 emulsified in CFA and treated with the TGF-β receptor kinase inhibitor IN-1130 (closed symbols) or PBS (open symbols) from 1–14 (A–C) or 3–14 (D) dpi. Daily bioluminescence and clinical assessment (weight loss, C; clinical score, D) were recorded in a blinded manner. Bioluminescence is shown from representative mice of each group individually (A) or as mean ± SEM (B). Similar results were obtained in 2 independent experiments. Data are shown as mean ± SEM.